Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

FDA says watch out for fake Ozempic, a diabetes drug used by many for weight loss

Thousands of fake units of the drug have been seized by the FDA, which is working alongside the manufacturer to test the counterfeit products for safety concerns.

WEKU

FDA warns that counterfeit Ozempic is flooding US supply chain

Officials have seized thousands of counterfeit units

The Independent UK

FDA Seizes Thousands of Counterfeit Ozempic Shots for Diabetes

Counterfeit Ozempic diabetes drug seized by FDA, prompting concerns over identity, quality, and safety. Report suspect packages to FDA hotline.

Top News

From analysis to the latest developments in health,
read the most diverse news in one place.

'I had to set two alarms at night to check my glucose to make sure I wouldn’t die': meet the revolutionary who won't stop until cycling is safer

The UCI banned his technology from races, yet Supersapiens boss Phil Southerland tells Chris Marshall-Bell he is still dead set on changing the sport in the most profound way for decades

Cycling Weekly

Weight loss from Lilly’s Zepbound drug reversed after stopping treatment, according to study

‘They gain back about half the weight they had originally lost over a one-year period of time,’ professor says

The Independent UK

Chasing Weight Loss Dream, Many In US Seek Ozempic Alternatives

Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity.

International Business Times

Wegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs

Weight-loss drug Wegovy faces high demand, limited supply, and tricky health care systems to navigate.

Fortune

Read news from The Economist, FT, and more,
with one subscription

3 Buy-Rated Healthcare Dividend Stocks for Income Investors

Looking for analysts' favorite stock picks in a traditionally defensive sector, with solid dividend payments to help boost your returns? Here's a look at three stocks for income investors to consider at current levels.

Barchart

Revealed: obesity jab maker discussed targeting benefit claimants with UK government

Drug firm Novo Nordisk proposed singling out those most likely to return to work with its weight-loss injection

The Guardian - UK

Germany considers banning Ozempic exports, including to U.S.

Germany exports Ozempic to the EU and the U.S., Karl Broich, president of the German Federal Institute for Drugs and Medical Devices, told Der Spiegel.

Fortune

Scientists have discovered a new benefit to Novo Nordisk’s weight-loss drug Wegovy: It can cut heart-related deaths by 20%, drugmaker reports

Wegovy was found to cut the risk of serious heart events by 20%—Novo Nordisk has now asked the U.S. FDA to reflect the heart benefits in the drug's label.

Fortune

Obesity drug Wegovy cut risk of serious heart problems by 20%, study finds

A new large study finds that the popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in certain patients

The Independent UK

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug

U.S. regulators signed off on Eli Lilly’s diabetes drug Zepbound, which can also be used to aid weight loss like Wegovy and Ozempic.

Fortune

AstraZeneca makes big push into weight-loss market with obesity pill deal

UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Newsroom.co.nz

How a 'Rule of Two' could remove our barrier to better drug access

We need to address the unnecessary and wasteful Medsafe approval for tried and tested drugs by much bigger regulatory authorities abroad, argues Dr Eric Crampton

Fortune

Novo Nordisk threatens to expand in US in row over EU rules

Novo Nordisk's CEO doesn't like proposed new EU rules that would cut the period for which drugmakers enjoy exclusivity for their products from 10 years to eight years.

Newcastle Herald

Ozempic's rebranded weight-loss drug should be available next year

'This is real and these medications are here to stay.'

Fortune

Novo Nordisk gives foodmakers $900 million reason to worry

Sales would have been higher if not for a shortfall following surging demand.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Sales soar at Danish firm behind weight-loss drug semaglutide

Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company

Barchart

3 'Strong Buy' Dividend Stocks That Are Beating the Market

Here are three top-rated dividend stocks that have outperformed the S&P 500 in the past month, despite a tough environment for equities.

The Independent UK

Warning as patients hospitalised after taking fake Ozempic weight-loss drug

Hundreds of fake Ozempic jabs from the black market have been seied by the regulator

Barchart

3 Top-Rated Growth Stocks To Buy on Every Dip

Growth stocks are down, but don't count them out. Here are three top-rated names worth scooping up when the market pulls back.

The Independent UK

Fears over black market weight loss drugs as people left seriously ill from counterfeit Ozempic

Austria’s criminal investigation service warned on Monday that fake injection pens may still be in circulation

AAP

Aust shares close a smidge higher to extend win streak

The local share market has technically extended its winning streak to six days, with seven of the ASX's 11 sectors finishing in the green.

Fortune

Wall Street is now betting against restaurant stocks because of Novo Nordisk’s Ozempic and high interest rates

Short positions on companies such as McDonald’s and Starbucks have increased in the last month, and weight loss drugs are part of the reason why.

1 … 18 19 20 21

People

Lars Fruergaard Jørgensen

18 stories

Ihor Dusaniwsky

14 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.